NASDAQ:OBSV - Obseva Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$12.89 -0.06 (-0.46 %)
(As of 05/27/2018 03:50 PM ET)
Previous Close$12.89
Today's Range$12.50 - $13.00
52-Week Range$5.00 - $15.81
Volume612,860 shs
Average Volume73,055 shs
Market Capitalization$478.62 million
P/E Ratio-5.73
Dividend YieldN/A
Beta2.82

About Obseva (NASDAQ:OBSV)

Obseva logoObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.

Receive OBSV News and Ratings via Email

Sign-up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OBSV
CUSIPN/A
Phone41-22-552-3840

Debt

Debt-to-Equity RatioN/A
Current Ratio8.35
Quick Ratio8.35

Price-To-Earnings

Trailing P/E Ratio-5.73
Forward P/E Ratio-6.23
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.83 per share
Price / Book4.55

Profitability

EPS (Most Recent Fiscal Year)($2.25)
Net Income$-66,920,000.00
Net MarginsN/A
Return on Equity-70.18%
Return on Assets-62.68%

Miscellaneous

Employees39
Outstanding Shares37,130,000

Obseva (NASDAQ:OBSV) Frequently Asked Questions

What is Obseva's stock symbol?

Obseva trades on the NASDAQ under the ticker symbol "OBSV."

How were Obseva's earnings last quarter?

Obseva SA (NASDAQ:OBSV) announced its quarterly earnings data on Wednesday, May, 16th. The company reported ($0.54) EPS for the quarter, missing the Zacks' consensus estimate of ($0.46) by $0.08. View Obseva's Earnings History.

When is Obseva's next earnings date?

Obseva is scheduled to release their next quarterly earnings announcement on Tuesday, August, 21st 2018. View Earnings Estimates for Obseva.

What price target have analysts set for OBSV?

5 analysts have issued twelve-month price objectives for Obseva's stock. Their predictions range from $18.00 to $27.00. On average, they expect Obseva's share price to reach $21.80 in the next year. View Analyst Ratings for Obseva.

What are Wall Street analysts saying about Obseva stock?

Here are some recent quotes from research analysts about Obseva stock:
  • 1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (5/22/2018)
  • 2. HC Wainwright analysts commented, "EDELWEISS Blooming Next Quarter; Reiterate Buy Stock Data Intraday 03/09/2018 Price $14.00 Exchange NASDAQ Price Target $27.00 52-Week High $15.81 52-Week Low $5.00 Enterprise Value (M) $409.2 Market Cap (M) $520 Public Market Float (M) 13.4 Shares Outstanding (M) 37.1 3 Month Avg Volume 35,780 Short Interest (M) 0.03 Balance Sheet Metrics Cash (M) $110.8 Total Debt (M) $0.0 Total Cash/Share $2.99 Book Value/Share $2.84 EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.22) (0.58) (0.45) 2Q — (0.61) (0.44) 3Q (0.30) (0.59) (0.51) 4Q (0.51) (0.48) (0.51) FY (1.40) (2.25) (1.92) 16 14 12 10 8 6 4 MAR- 17 J UL- 17 NOV- 17 MAR- 18 2 1.5 1 0.5 0 Vol. (mil) Price Financial results reported—net loss in-line with forecast. This morning, ObsEva S.A. reported its financial results for the fourth quarter and full-year 2017." (3/9/2018)

Who are some of Obseva's key competitors?

Who are Obseva's key executives?

Obseva's management team includes the folowing people:
  • Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 66)
  • Mr. Timothy M. Adams, Chief Financial Officer (Age 58)
  • Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer (Age 53)
  • Mr. Mario Vincent Corso, Sr. Director of Investor Relations
  • Dr. Elke Bestel M.D., Chief Medical Officer and Head of Pharmacovigilance (Age 52)

When did Obseva IPO?

(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Has Obseva been receiving favorable news coverage?

News articles about OBSV stock have trended somewhat positive on Sunday, Accern Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Obseva earned a daily sentiment score of 0.08 on Accern's scale. They also assigned media headlines about the company an impact score of 46.31 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Obseva's major shareholders?

Obseva's stock is owned by many different of retail and institutional investors. Top institutional investors include Sofinnova Ventures Inc (12.79%), VHCP Management II LLC (5.77%), Sphera Funds Management LTD. (2.01%) and DRW Securities LLC (0.06%). View Institutional Ownership Trends for Obseva.

Which institutional investors are buying Obseva stock?

OBSV stock was bought by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Sphera Funds Management LTD., VHCP Management II LLC and DRW Securities LLC. View Insider Buying and Selling for Obseva.

How do I buy shares of Obseva?

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Obseva's stock price today?

One share of OBSV stock can currently be purchased for approximately $12.89.

How big of a company is Obseva?

Obseva has a market capitalization of $478.62 million. The company earns $-66,920,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Obseva employs 39 workers across the globe.

How can I contact Obseva?

Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]


MarketBeat Community Rating for Obseva (OBSV)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  112 (Vote Underperform)
Total Votes:  223
MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Obseva (NASDAQ:OBSV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Obseva in the last 12 months. Their average twelve-month price target is $21.80, suggesting that the stock has a possible upside of 69.12%. The high price target for OBSV is $27.00 and the low price target for OBSV is $18.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.80$21.80$20.20$20.40
Price Target Upside: 69.12% upside56.16% upside83.64% upside88.34% upside

Obseva (NASDAQ:OBSV) Consensus Price Target History

Price Target History for Obseva (NASDAQ:OBSV)

Obseva (NASDAQ:OBSV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018HC WainwrightReiterated RatingBuy$27.00LowView Rating Details
2/27/2018BMO Capital MarketsReiterated RatingBuy$24.00HighView Rating Details
2/27/2018Leerink SwannBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $18.00HighView Rating Details
2/27/2018Credit Suisse GroupReiterated RatingOutperform ➝ Buy$16.00 ➝ $18.00LowView Rating Details
11/2/2017Royal Bank of CanadaReiterated RatingBuy$22.00N/AView Rating Details
2/21/2017Jefferies GroupInitiated CoverageBuy ➝ Buy$21.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Obseva (NASDAQ:OBSV) Earnings History and Estimates Chart

Earnings by Quarter for Obseva (NASDAQ:OBSV)

Obseva (NASDAQ:OBSV) Earnings Estimates

2018 EPS Consensus Estimate: ($2.33)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.54)($0.54)($0.54)
Q2 20182($0.58)($0.55)($0.57)
Q3 20182($0.63)($0.56)($0.60)
Q4 20182($0.69)($0.56)($0.63)

Obseva (NASDAQ OBSV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018($0.47)N/AView Earnings Details
5/16/20183/31/2018($0.46)($0.54)$0.01 millionViewListenView Earnings Details
3/9/2018Before Market($0.56)($0.48)$0.01 millionViewN/AView Earnings Details
11/14/2017n/a($0.58)($0.59)ViewN/AView Earnings Details
8/15/20176/30/2017($0.48)($0.61)$0.01 millionViewN/AView Earnings Details
5/18/20173/31/2017($0.41)($0.58)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Obseva (NASDAQ:OBSV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Obseva (NASDAQ OBSV) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 66.07%
Insider Trading History for Obseva (NASDAQ:OBSV)
Institutional Ownership by Quarter for Obseva (NASDAQ:OBSV)

Obseva (NASDAQ OBSV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Obseva (NASDAQ OBSV) News Headlines

Source:
DateHeadline
Head-To-Head Contrast: Obseva (OBSV) and Revance Therapeutics (RVNC)Head-To-Head Contrast: Obseva (OBSV) and Revance Therapeutics (RVNC)
www.americanbankingnews.com - May 25 at 3:25 PM
ObsEva (OBSV) Given Consensus Rating of "Buy" by AnalystsObsEva (OBSV) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 22 at 1:34 AM
Research Analysts Offer Predictions for ObsEvas Q2 2018 Earnings (OBSV)Research Analysts Offer Predictions for ObsEva's Q2 2018 Earnings (OBSV)
www.americanbankingnews.com - May 21 at 1:04 AM
Edited Transcript of OBSV.O earnings conference call or presentation 16-May-18 12:00pm GMTEdited Transcript of OBSV.O earnings conference call or presentation 16-May-18 12:00pm GMT
finance.yahoo.com - May 18 at 10:40 AM
ObsEva SA Ordinary Shares (OBSV) Q1 2018 Earnings Conference Call TranscriptObsEva SA Ordinary Shares (OBSV) Q1 2018 Earnings Conference Call Transcript
www.fool.com - May 17 at 7:57 PM
ObsEva SA: ObsEva Reports First Quarter 2018 Financial Results and Provides Business UpdateObsEva SA: ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
www.finanznachrichten.de - May 16 at 4:18 PM
ObsEva (OBSV) CEO Ernest Loumaye Q1 2018 Results - Earnings Call TranscriptObsEva' (OBSV) CEO Ernest Loumaye Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 16 at 4:18 PM
ObsEva (OBSV) Posts  Earnings Results, Misses Expectations By $0.08 EPSObsEva (OBSV) Posts Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - May 16 at 12:56 PM
ObsEva SA (OBSV)ObsEva SA (OBSV)
finance.yahoo.com - May 16 at 9:55 AM
With A -121.60% Earnings Drop, Did ObsEva SA (NASDAQ:OBSV) Really Underperform?With A -121.60% Earnings Drop, Did ObsEva SA (NASDAQ:OBSV) Really Underperform?
finance.yahoo.com - May 16 at 9:55 AM
ObsEva Reports First Quarter 2018 Financial Results and Provides Business UpdateObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
finance.yahoo.com - May 16 at 9:55 AM
ObsEva (OBSV) to Release Quarterly Earnings on WednesdayObsEva (OBSV) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 10 at 1:00 PM
ObsEva (OBSV) Upgraded to "Hold" by ValuEngineObsEva (OBSV) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - May 2 at 11:07 PM
ObsEva (OBSV) Receives Average Recommendation of "Buy" from AnalystsObsEva (OBSV) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 27 at 1:29 AM
ObsEva (OBSV) Upgraded at Zacks Investment ResearchObsEva (OBSV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 17 at 12:40 AM
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York CityObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City
feeds.benzinga.com - April 16 at 7:46 AM
ObsEva (OBSV) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowObsEva (OBSV) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 4:19 PM
ObsEva (OBSV) Rating Reiterated by HC WainwrightObsEva (OBSV) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - April 7 at 10:28 PM
ObsEva (OBSV) Rating Increased to Buy at Zacks Investment ResearchObsEva (OBSV) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 6 at 6:29 PM
ObsEva (OBSV) Given Average Recommendation of "Buy" by BrokeragesObsEva (OBSV) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 2 at 1:30 AM
Obseva (OBSV) PT Set at $25.00 by HC WainwrightObseva (OBSV) PT Set at $25.00 by HC Wainwright
www.americanbankingnews.com - March 30 at 3:58 PM
Obseva (OBSV) Rating Lowered to Sell at Zacks Investment ResearchObseva (OBSV) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 24 at 12:06 PM
Edited Transcript of OBSV.O earnings conference call or presentation 9-Mar-18 1:00pm GMTEdited Transcript of OBSV.O earnings conference call or presentation 9-Mar-18 1:00pm GMT
finance.yahoo.com - March 18 at 9:36 AM
Obseva (OBSV) Raised to "Hold" at Zacks Investment ResearchObseva (OBSV) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 17 at 7:48 PM
Obseva (OBSV) Announces  Earnings Results, Beats Estimates By $0.08 EPSObseva (OBSV) Announces Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - March 9 at 11:46 PM
Obsevas (OBSV) Buy Rating Reiterated at HC WainwrightObseva's (OBSV) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - March 9 at 8:36 PM
ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business UpdateObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 9 at 10:19 AM
Obseva SA (OBSV) Given Consensus Recommendation of "Buy" by BrokeragesObseva SA (OBSV) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 8 at 1:24 AM
Obseva SA (OBSV) Shares Bought by VHCP Management II LLCObseva SA (OBSV) Shares Bought by VHCP Management II LLC
www.americanbankingnews.com - March 6 at 10:51 AM
Obseva (OBSV) to Release Quarterly Earnings on FridayObseva (OBSV) to Release Quarterly Earnings on Friday
www.americanbankingnews.com - March 5 at 6:10 PM
ObsEva SA to Hold Fourth Quarter and Year-end 2017 Financial Results and Business Update Call on March 9, 2018ObsEva SA to Hold Fourth Quarter and Year-end 2017 Financial Results and Business Update Call on March 9, 2018
finance.yahoo.com - March 2 at 9:33 AM
Leerink Swann Weighs in on Obseva SAs FY2020 Earnings (OBSV)Leerink Swann Weighs in on Obseva SA's FY2020 Earnings (OBSV)
www.americanbankingnews.com - March 1 at 3:50 PM
Wired News – ObsEva Released Positive Top-line Results from IMPLANT2 Phase-3 Clinical Trial Evaluating Nolasiban in IVFWired News – ObsEva Released Positive Top-line Results from IMPLANT2 Phase-3 Clinical Trial Evaluating Nolasiban in IVF
finance.yahoo.com - February 28 at 9:36 AM
Obseva (OBSV) Price Target Raised to $18.00Obseva (OBSV) Price Target Raised to $18.00
www.americanbankingnews.com - February 27 at 3:30 PM
Obsevas (OBSV) "Buy" Rating Reiterated at BMO Capital MarketsObseva's (OBSV) "Buy" Rating Reiterated at BMO Capital Markets
www.americanbankingnews.com - February 27 at 12:39 PM
Obseva (OBSV) Price Target Increased to $18.00 by Analysts at Leerink SwannObseva (OBSV) Price Target Increased to $18.00 by Analysts at Leerink Swann
www.americanbankingnews.com - February 27 at 12:24 PM
ARCA biopharma And ObsEva Just Put Out Clinical Trial DataARCA biopharma And ObsEva Just Put Out Clinical Trial Data
finance.yahoo.com - February 26 at 4:48 PM
ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVFObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF
finance.yahoo.com - February 26 at 9:34 AM
ObsEva SA (OBSV) to Announce Topline Results of IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF/ICSI on MondayObsEva SA (OBSV) to Announce Topline Results of IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday
www.streetinsider.com - February 24 at 4:33 PM
ObsEva conference call Monday on late-stage Nolasiban dataObsEva conference call Monday on late-stage Nolasiban data
seekingalpha.com - February 24 at 4:33 PM
ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018
finance.yahoo.com - February 23 at 4:44 PM
Reviewing Dimension Therapeutics (DMTX) and Obseva (OBSV)Reviewing Dimension Therapeutics (DMTX) and Obseva (OBSV)
www.americanbankingnews.com - February 19 at 5:10 AM
ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018
finance.yahoo.com - February 15 at 8:54 AM
Obseva SA (OBSV) Receives Average Rating of "Buy" from BrokeragesObseva SA (OBSV) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 11 at 1:28 AM
Obseva (OBSV) Stock Rating Reaffirmed by HC WainwrightObseva (OBSV) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - February 5 at 7:40 PM
Dr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasonsDr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasons
finance.yahoo.com - February 1 at 9:04 AM
ObsEva SA (OBSV) Given Consensus Rating of "Buy" by AnalystsObsEva SA (OBSV) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - January 17 at 1:48 AM
Head-To-Head Review: ObsEva (OBSV) versus Its PeersHead-To-Head Review: ObsEva (OBSV) versus Its Peers
www.americanbankingnews.com - January 12 at 3:16 AM
ObsEva (OBSV) versus The Competition Head to Head ReviewObsEva (OBSV) versus The Competition Head to Head Review
www.americanbankingnews.com - January 7 at 11:26 PM
Comparing Athersys (ATHX) & ObsEva (OBSV)Comparing Athersys (ATHX) & ObsEva (OBSV)
www.americanbankingnews.com - December 27 at 1:16 PM

SEC Filings

Obseva (NASDAQ:OBSV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Obseva (NASDAQ:OBSV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Obseva (NASDAQ OBSV) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.